Amedeo Smart

Free Medical Literature Service

 

Amedeo

Head and Neck Cancer
  Free Subscription

Articles published in
J Clin Endocrinol Metab
    February 2026
  1. PRETE A, Matrone A, Romei C, Gambale C, et al
    Calcitonin Thresholds for Prediction of Medullary Thyroid Carcinoma and its Clinical Response in MEN2A Gene Carriers.
    J Clin Endocrinol Metab. 2026 Feb 14:dgag041. doi: 10.1210.
    >> Share

    December 2025
  2. MACHLAH YM, Brandenburg T, Muchalla P, Tiedje V, et al
    Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center.
    J Clin Endocrinol Metab. 2025;111:167-179.
    >> Share

    November 2025
  3. DAN R, Paran N, Vinegrad N, Fraenkel M, et al
    Parity as a Risk Factor for Differentiated Thyroid Carcinoma- A Population-Based Study.
    J Clin Endocrinol Metab. 2025 Nov 24:dgaf642. doi: 10.1210.
    >> Share

  4. LEE JS, Kim NK, Jeong HJ, Yun HJ, et al
    Impact of Subtype Variability on Clinical Features in Papillary Thyroid Cancer.
    J Clin Endocrinol Metab. 2025 Nov 19:dgaf531. doi: 10.1210.
    >> Share

  5. SONG JX, Xie J, Zhou JX, Zhang YF, et al
    Approach to the Patient With Primary Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1.
    J Clin Endocrinol Metab. 2025;110:3546-3558.
    >> Share

  6. YU CY, Chu EH, Lin CH, Chen YC, et al
    Diagnostic Efficiency of Thyroglobulin in Lymph Node Fine-needle Aspiration Washout: A Systematic Review and Meta-analysis.
    J Clin Endocrinol Metab. 2025;110:3569-3587.
    >> Share

  7. DEVOUGE AC, Lasolle H, Dupin C, Vergniol J, et al
    Outcomes and Therapeutic Strategies for Head-and-neck Paragangliomas Associated With Succinate Dehydrogenase Mutations.
    J Clin Endocrinol Metab. 2025;110:e4030-e4037.
    >> Share

  8. SOTO JACOME C, Arce-Camposano A, Toro-Tobon D, Al Zahidy M, et al
    Drug Repurposing for Reducing the Size of Benign Thyroid Nodules: A Systematic Review.
    J Clin Endocrinol Metab. 2025 Nov 12:dgaf616. doi: 10.1210.
    >> Share

    October 2025
  9. CASALINI R, Romei C, Bottici V, Cappagli V, et al
    Prevalence and genetics of "de novo" MEN2 syndromes.
    J Clin Endocrinol Metab. 2025;110:e3559-e3565.
    >> Share

    September 2025
  10. POZDEYEV N, White SL, Bell CC, Haugen BR, et al
    Artificial intelligence applications in thyroid cancer care.
    J Clin Endocrinol Metab. 2025 Sep 25:dgaf530. doi: 10.1210.
    >> Share

  11. VALENCIAGA A, Liyanarachchi S, Brock PL, Ringel MD, et al
    Long-term outcomes of patients diagnosed with differentiated thyroid cancer in childhood and young adulthood.
    J Clin Endocrinol Metab. 2025 Sep 18:dgaf522. doi: 10.1210.
    >> Share

  12. XU X, Zhang C, Wang G, Dong B, et al
    Correlation of TgAb With Clinicopathological Features and Unfavorable Efficacy of 131I Ablation in PTC.
    J Clin Endocrinol Metab. 2025;110:e3245-e3251.
    >> Share

  13. REDLICH A, Pfaehler E, Kunstreich M, Schmutz M, et al
    ML Prediction of Recurrence in Pediatric Thyroid Cancer: MET Cohort Analysis Using XGBoost and SHAP.
    J Clin Endocrinol Metab. 2025 Sep 1:dgaf487. doi: 10.1210.
    >> Share

    August 2025
  14. CHO YY, Ahn SH, Kim M, Lee EK, et al
    TSH Cut-Offs and Recurrence Risk in Differentiated Thyroid Carcinomas: A Systematic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2025 Aug 14:dgaf463. doi: 10.1210.
    >> Share

  15. BILGIN C, Hibbert R, Oztepe F, Sfeir JG, et al
    Percutaneous Ablation of Parathyroid Adenomas: A Systematic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2025;110:e3150-e3162.
    >> Share

    July 2025
  16. GREENSPUN BC, Metzger DA, Lee S, Pearson BE, et al
    Long Term Survivors of Anaplastic Thyroid Cancer: A Genomic Predictive Model.
    J Clin Endocrinol Metab. 2025 Jul 15:dgaf391. doi: 10.1210.
    >> Share

  17. BODOQUE-CUBAS J, Fernandez-Saez J, Martinez-Hervas S, Perez-Lacasta MJ, et al
    Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-Effectiveness Analysis.
    J Clin Endocrinol Metab. 2025 Jul 12:dgaf399. doi: 10.1210.
    >> Share

    June 2025
  18. HAMIDI S, Maniakas A, Akhave NS, Banuchi VE, et al
    Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues.
    J Clin Endocrinol Metab. 2025 Jun 26:dgaf366. doi: 10.1210.
    >> Share

  19. YAMAZAKI H, Sugino K, Katoh R, Matsuzu K, et al
    Clinical Significance of Successful Ablation in Follicular Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Jun 4:dgaf326. doi: 10.1210.
    >> Share

    May 2025
  20. NISHIKAWA Y, Oguro F, Suzuki C, Kobashi Y, et al
    Stable iodine intake and thyroid screening outcomes after the Fukushima Nuclear Disaster: an observational study.
    J Clin Endocrinol Metab. 2025 May 29:dgaf312. doi: 10.1210.
    >> Share

  21. FRICH PS, Sigstad E, Berstad AE, Opsahl EM, et al
    Ethanol Ablation of Metastatic Lymph Nodes in Patients with Papillary Thyroid Carcinoma - Predictors of Clinical Outcome.
    J Clin Endocrinol Metab. 2025 May 23:dgaf298. doi: 10.1210.
    >> Share

    April 2025
  22. WHITE SL, Jamil T, Bell C, Fishbein L, et al
    Population prevalence of the major thyroid cancer-associated syndromes.
    J Clin Endocrinol Metab. 2025 Apr 15:dgaf236. doi: 10.1210.
    >> Share

  23. HIRUMA S, Watanabe N, Noh JY, Hirose R, et al
    Occurrence of Newly Diagnosed Thyroid Cancer Is Not Increased After Radioactive Iodine Therapy for Graves' Disease.
    J Clin Endocrinol Metab. 2025 Apr 11:dgaf231. doi: 10.1210.
    >> Share

  24. KU EJ, Lee J, Yoo WS, Bae J, et al
    Long-Term Non-skeletal Complications in Patients with Thyroid Cancer and Hypoparathyroidism Post-total Thyroidectomy.
    J Clin Endocrinol Metab. 2025 Apr 2:dgaf213. doi: 10.1210.
    >> Share

  25. DE LEO S, Brigante G, D'Elia S, Censi S, et al
    Prospective Validation of ATA Risk Score for Papillary Thyroid Microcarcinoma: An ITCO Real-World Study.
    J Clin Endocrinol Metab. 2025 Apr 1:dgaf190. doi: 10.1210.
    >> Share

    March 2025
  26. SHARIQ OA, Waguespack SG, Hamidi S, Kensing BC, et al
    Approach to the Patient: Hereditary Medullary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Mar 19:dgaf089. doi: 10.1210.
    >> Share

  27. SIMONDS WF, Li Y, Jha S
    Genotype-Phenotype Correlations in the Hyperparathyroidism-Jaw Tumor Syndrome.
    J Clin Endocrinol Metab. 2025;110:931-939.
    >> Share

  28. AEKKA A, Arva NC, Ren HZ, Raval M, et al
    Multiplatform Molecular Testing as an Adjunct to Fine Needle Aspiration in the Evaluation of Pediatric Thyroid Nodules.
    J Clin Endocrinol Metab. 2025 Mar 4:dgaf110. doi: 10.1210.
    >> Share

    February 2025
  29. SCAPPATICCIO L, Di Martino N, Ferrazzano P, Maiorino MI, et al
    Prevalence and Management of Complications of Laser Ablation for Benign Thyroid Nodules: A Systematic Review of Literature and Meta-analysis.
    J Clin Endocrinol Metab. 2025 Feb 20:dgaf108. doi: 10.1210.
    >> Share

  30. GOLDFARB M, Bustos MA, Moon J, Jackson K, et al
    Pilot Study of Plasma miRNA Signature Panel for Differentiating Single vs Multiglandular Parathyroid Disease.
    J Clin Endocrinol Metab. 2025;110:758-770.
    >> Share

  31. LAI ST, Bauer AJ
    Approach to the Pediatric Patient with Thyroid Nodules.
    J Clin Endocrinol Metab. 2025 Feb 13:dgaf090. doi: 10.1210.
    >> Share

  32. ZHOU J, Li D, Ren J, Huang C, et al
    Machine Learning: A Multicentre Study on Predicting Lateral Lymph Node Metastasis in cN0 Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2025 Feb 8:dgaf070. doi: 10.1210.
    >> Share

  33. WANG L, Zhang L, Ma R, Zhang Y, et al
    Semaglutide reprograms macrophages via the GLP-1R/PPARG/ACSL1 pathway to suppress papillary thyroid carcinoma growth.
    J Clin Endocrinol Metab. 2025 Feb 5:dgaf053. doi: 10.1210.
    >> Share

  34. CIRELLO V, Colombo C, Tosi D, Manzo A, et al
    TP53 Alterations Associate with Poor Response to Lenvatinib in Patients with Advanced Thyroid Cancer.
    J Clin Endocrinol Metab. 2025 Feb 1:dgaf056. doi: 10.1210.
    >> Share

    January 2025
  35. TELITI M, Chytiris S, Coperchini F, Cerutti M, et al
    The natural history of cytologically low-risk indeterminate thyroid nodules.
    J Clin Endocrinol Metab. 2025 Jan 29:dgaf052. doi: 10.1210.
    >> Share

  36. VAN DER MEEREN MMD, Boers T, de Graaf P, Duvivier KM, et al
    Radiofrequency ablation for thyroid nodules (RATED study) - analysis of a learning curve and predictors of success.
    J Clin Endocrinol Metab. 2025 Jan 29:dgaf058. doi: 10.1210.
    >> Share

  37. LI Y, Simonds WF, Chen H
    A Comparative Genomic Analysis of Parathyroid Adenomas and Carcinomas Harboring Heterozygous Germline CDC73 Mutations.
    J Clin Endocrinol Metab. 2025;110:429-440.
    >> Share

  38. NAKAI T, Horiuchi K, Okamoto T
    Predicting Tumor Volume in Primary Hyperparathyroidism From Preoperative Clinical Data.
    J Clin Endocrinol Metab. 2025;110:e391-e396.
    >> Share

  39. SONG JX, Dong YQ, Han RL, Xie J, et al
    PI3K/AKT/mTOR Activation is Associated with Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas.
    J Clin Endocrinol Metab. 2025 Jan 20:dgaf042. doi: 10.1210.
    >> Share

  40. ROBENSHTOK E, Bachar G, Ritter A
    Approach to the Patient with Thyroid Cancer: Selection and Management of Candidates for Lobectomy.
    J Clin Endocrinol Metab. 2025 Jan 2:dgae903. doi: 10.1210.
    >> Share

    November 2024
  41. CHEN Z, Sun W, Fei M, Qian K, et al
    Clinical and Sonographic Differences between RET Fusion-Positive and BRAFV600E in Papillary Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2024 Nov 18:dgae803. doi: 10.1210.
    >> Share

  42. SCHUMM MA, Nikiforov YE, Nikiforova MN, Wald AI, et al
    Association of BRAF V600E allele frequency with clinicopathologic outcomes in papillary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Nov 14:dgae774. doi: 10.1210.
    >> Share


  43. Correction to: "Prognostic Analysis of 131I Efficacy After Papillary Thyroid Carcinoma Surgery Based on CT Radiomics".
    J Clin Endocrinol Metab. 2024 Nov 1:dgae756. doi: 10.1210.
    >> Share

    October 2024
  44. MENG L, Li H, Fu Y, Yu D, et al
    Somatic DICER1-Mutant Benign Thyroid Nodules in Adults: A Group of Follicular Nodular Disease With Continuous Growth.
    J Clin Endocrinol Metab. 2024 Oct 28:dgae750. doi: 10.1210.
    >> Share

  45. PARVATHAREDDY SK, Siraj AK, Qadri Z, Siraj N, et al
    The Prognostic Impact of Tumor Size and BRAF Mutational Status in Middle Eastern Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Oct 18:dgae740. doi: 10.1210.
    >> Share


  46. Correction to: "Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine".
    J Clin Endocrinol Metab. 2024 Oct 16:dgae717. doi: 10.1210.
    >> Share

  47. BEHAIRY N, Leonardi AJ, Gubbi S, Kumari S, et al
    Tumor Volume Doubling Time of Less Than One Year is Associated with a Higher Risk of Death from Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Oct 16:dgae733. doi: 10.1210.
    >> Share

  48. KELLY CA, Sipos JA
    Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists.
    J Clin Endocrinol Metab. 2024 Oct 14:dgae722. doi: 10.1210.
    >> Share

  49. LEE S, Antunez AG, Sinco B, Saucke MC, et al
    Cancer-related Fear and Worry in Patients with Low-Risk Thyroid Cancer: A Longitudinal Cohort Study.
    J Clin Endocrinol Metab. 2024 Oct 14:dgae688. doi: 10.1210.
    >> Share

  50. HSU YC, Kuo CY, Chien MN, Jhuang JY, et al
    Overexpression of NR1D1 portends disease recurrence in thyroid cancer.
    J Clin Endocrinol Metab. 2024 Oct 3:dgae687. doi: 10.1210.
    >> Share

  51. MEHANNA H, Nankivell P, Boelaert K, Woolley R, et al
    Diagnostic performance of ultrasound vs. ultrasound-guided FNAc in thyroid nodules: data from the ElaTION trial.
    J Clin Endocrinol Metab. 2024 Oct 3:dgae682. doi: 10.1210.
    >> Share

  52. ROTONDI M, Endo M, Teliti M, Crescenzi A, et al
    Beyond malignancy risk stratification: FNAC report anticipates thyroid cancer staging. Insights from recent studies.
    J Clin Endocrinol Metab. 2024 Oct 1:dgae675. doi: 10.1210.
    >> Share

    September 2024
  53. MORETTI S, Mandarano M, Menicali E, Guzzetti M, et al
    Wnt/B-catenin activation and TP53 mutations associate with distinct immune profiles in advanced thyroid cancer.
    J Clin Endocrinol Metab. 2024 Sep 27:dgae667. doi: 10.1210.
    >> Share

  54. XU B, Baine MK, Jungbluth A, Alabkaa A, et al
    Detection of SEZ6, a therapeutic target, in medullary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Sep 26:dgae672. doi: 10.1210.
    >> Share

  55. ZHANG Y, Zhang X, Lin L, Xing M, et al
    Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    J Clin Endocrinol Metab. 2024 Sep 18:dgae617. doi: 10.1210.
    >> Share

  56. MACIEL AAW, Danilovic DLS, Soares IC, Freitas TC, et al
    Association between papillary thyroid cancer and primary aldosteronism in individuals with hypertension.
    J Clin Endocrinol Metab. 2024 Sep 18:dgae653. doi: 10.1210.
    >> Share

    August 2024
  57. YUAN J, Chen Z, Zhang J, Chen X, et al
    Preoperative Serum Lipids as Novel Predictors of Survival in 3575 Papillary Thyroid Cancer Patients.
    J Clin Endocrinol Metab. 2024 Aug 30:dgae601. doi: 10.1210.
    >> Share

  58. MOOIJ CF, Zwaveling-Soonawala N, Hillebrand JJ, van Trotsenburg ASP, et al
    Approach to the Patient: Challenging Cases of Pediatric Thyrotoxicosis.
    J Clin Endocrinol Metab. 2024 Aug 27:dgae592. doi: 10.1210.
    >> Share

  59. RAMONE T, Ghirri A, Prete A, Matrone A, et al
    Molecular profiling of low-risk papillary thyroid carcinoma (mPTC) on active surveillance.
    J Clin Endocrinol Metab. 2024 Aug 24:dgae575. doi: 10.1210.
    >> Share

  60. XU Y, Gao J, Wang N, Zedenius J, et al
    BRAF-induced EHF expression affects TERT in aggressive papillary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Aug 24:dgae589. doi: 10.1210.
    >> Share

  61. STEGENGA MT, Oudijk L, van Velsen EFS, Peeters RP, et al
    Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification.
    J Clin Endocrinol Metab. 2024 Aug 21:dgae581. doi: 10.1210.
    >> Share

  62. CASTELLANOS LE, Zafereo ME, Sturgis EM, Wang JR, et al
    Pediatric Papillary Thyroid Carcinoma: Outcomes After Surgery Without Adjuvant Radioactive Iodine.
    J Clin Endocrinol Metab. 2024 Aug 20:dgae576. doi: 10.1210.
    >> Share

  63. GRANI G, D'Elia S, Puxeddu E, Morelli S, et al
    Data-Driven Thyroglobulin Cutoffs for Low- and Intermediate-Risk Thyroid Cancer Follow-Up: ITCO Real-World Analysis.
    J Clin Endocrinol Metab. 2024 Aug 16:dgae559. doi: 10.1210.
    >> Share

  64. IYER PC, Dadu R, Barque A, Zanelli C, et al
    Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay.
    J Clin Endocrinol Metab. 2024;109:2269-2273.
    >> Share

  65. LI G, Ye Z, Wei T, Zhu J, et al
    Clinical Outcomes and Implications of Radioactive Iodine Therapy on Cancer-specific Survival in WHO Classification of FTC.
    J Clin Endocrinol Metab. 2024;109:2294-2305.
    >> Share

  66. ENDO M, Peng J, Nabhan FA, Brock P, et al
    Indolent Behavior of Malignant Bethesda III Nodules Compared to Bethesda V/VI Nodules.
    J Clin Endocrinol Metab. 2024;109:2317-2324.
    >> Share

  67. KONDA B, Sherman EJ, Massarelli E, Nieva J, et al
    Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2024 Aug 12:dgae512. doi: 10.1210.
    >> Share

  68. GHOSH R, Auh S, Gubbi S, Veeraraghavan P, et al
    Association of Free Thyroxine with Progression-Free Survival in Intermediate and High Risk Differentiated Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Aug 8:dgae537. doi: 10.1210.
    >> Share

  69. WANG JR, Zafereo ME, Cabanillas ME, Wu CC, et al
    The association between thyroid differentiation score and survival outcomes in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Aug 1:dgae532. doi: 10.1210.
    >> Share

    July 2024
  70. FENG J, Wu C, Shen F, Cai W, et al
    Second Primary Differentiated Thyroid Carcinoma in Adult Cancer Survivors: A SEER Database Analysis.
    J Clin Endocrinol Metab. 2024 Jul 24:dgae501. doi: 10.1210.
    >> Share

  71. WANG H, Li Q, Tian T, Liu B, et al
    Improving the Risk Prediction of the 2015 ATA Recurrence Risk Stratification in Papillary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Jul 9:dgae465. doi: 10.1210.
    >> Share

  72. JING R, Wu N, Wu Y, Zhang Q, et al
    Efficacy and safety of multikinase inhibitors for patients with refractory thyroid cancer: Systematic review and network meta-analysis.
    J Clin Endocrinol Metab. 2024 Jul 6:dgae454. doi: 10.1210.
    >> Share


  73. Correction to: "TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma".
    J Clin Endocrinol Metab. 2024 Jul 1:dgae442. doi: 10.1210.
    >> Share

    June 2024
  74. SEHGAL K, Serritella A, Liu M, ONeill A, et al
    A phase I/II trial of sapanisertib in advanced anaplastic and radioiodine refractory differentiated thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Jun 29:dgae443. doi: 10.1210.
    >> Share

  75. PARDI E, Poma AM, Torregrossa L, Pierotti L, et al
    Whole-exome sequencing of atypical parathyroid tumors detects novel and common genes linked to parathyroid tumorigenesis.
    J Clin Endocrinol Metab. 2024 Jun 28:dgae441. doi: 10.1210.
    >> Share

  76. WILLIAMS MD, Liu Z, Rossi ED, Agarwal S, et al
    Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents.
    J Clin Endocrinol Metab. 2024 Jun 14:dgae354. doi: 10.1210.
    >> Share

    May 2024
  77. CAO H, Shangguan L, Zhu H, Hu C, et al
    Prognostic analysis of 131I efficacy after papillary thyroid carcinoma surgery based on CT radiomics.
    J Clin Endocrinol Metab. 2024 May 27:dgae364. doi: 10.1210.
    >> Share

  78. LEVESQUE F, Payne RJ, Beaudoin D, Boucher A, et al
    A Prospective Study of Publicly Funded Molecular Testing of Indeterminate Thyroid Nodules: Canada's Experience.
    J Clin Endocrinol Metab. 2024 May 23:dgae355. doi: 10.1210.
    >> Share

  79. LI G, Chen W, Jiang K, Huang J, et al
    Exosome-mediated Delivery of miR-519e-5p Promotes Malignant Tumor Phenotype and CD8+ T-Cell Exhaustion in Metastatic PTC.
    J Clin Endocrinol Metab. 2024;109:1601-1617.
    >> Share

  80. XIAN K, Xu S, Huang H, Xing C, et al
    Synergy of nodal factors in predicting recurrence after treatment of N1b papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 May 15:dgae329. doi: 10.1210.
    >> Share

  81. ZHANG W, Lin S, Wang Z, Zhang W, et al
    Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targets in Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 May 13:dgae327. doi: 10.1210.
    >> Share

    April 2024
  82. PETROVIC I, LoPresti J, Fatemi S, Gianoukakis A, et al
    Influence of Thyroglobulin (Tg) Autoantibodies on Tg levels Measured by Different Methodologies: (IMA, LC-MS/MS and RIA).
    J Clin Endocrinol Metab. 2024 Apr 30:dgae286. doi: 10.1210.
    >> Share

  83. SANT VR, Radhachandran A, Ivezic V, Lee DT, et al
    From Bench-to-Bedside: How Artificial Intelligence Is Changing Thyroid Nodule Diagnostics.
    J Clin Endocrinol Metab. 2024 Apr 29:dgae277. doi: 10.1210.
    >> Share

  84. ABOU AZAR S, Tobias J, Applewhite M, Angelos P, et al
    Medullary Thyroid Cancer: Single Institute Experience over Three Decades and Risk Factors for Recurrence.
    J Clin Endocrinol Metab. 2024 Apr 23:dgae279. doi: 10.1210.
    >> Share

  85. CHO YY, Ahn SH, Lee EK, Park YJ, et al
    Malignancy Risk of Follicular Neoplasm (Bethesda IV) With Variable Cutoffs of Tumor Size: A Systemic Review and Meta-Analysis.
    J Clin Endocrinol Metab. 2024;109:1383-1392.
    >> Share

  86. TODA S, Hiroshima Y, Iwasaki H, Masudo K, et al
    Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan.
    J Clin Endocrinol Metab. 2024 Apr 17:dgae271. doi: 10.1210.
    >> Share

  87. SAKO A, Matsuse M, Saenko V, Tanaka A, et al
    TERT promoter mutations increase tumor aggressiveness by altering TERT mRNA splicing in papillary thyroid carcinoma.
    J Clin Endocrinol Metab. 2024 Apr 5:dgae220. doi: 10.1210.
    >> Share

  88. LIU CQ, Shen CK, Du YX, Li ZM, et al
    Survival outcome and optimal candidates of primary tumor resection for patients with metastatic medullary thyroid cancer.
    J Clin Endocrinol Metab. 2024 Apr 4:dgae214. doi: 10.1210.
    >> Share

    March 2024
  89. LEE-SAXTON YJ, Egan CE, Bratton BA, Thiesmeyer JW, et al
    Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence.
    J Clin Endocrinol Metab. 2024 Mar 30:dgae203. doi: 10.1210.
    >> Share

  90. MAROTTA V, Rocco D, Crocco A, Deiana MG, et al
    Survival predictors of radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the real-life.
    J Clin Endocrinol Metab. 2024 Mar 19:dgae181. doi: 10.1210.
    >> Share

  91. OHIRA T, Nagao M, Hayashi F, Shimura H, et al
    Effects of Overweight on Risk of Thyroid Nodules in Children and Adolescents: The Fukushima Health Management Survey.
    J Clin Endocrinol Metab. 2024 Mar 13:dgae161. doi: 10.1210.
    >> Share

  92. CHEN H, Liu Y, Wang F, Sun J, et al
    MeIS: DNA methylation-based immune response signatures for thyroid nodule diagnostics.
    J Clin Endocrinol Metab. 2024 Mar 7:dgae141. doi: 10.1210.
    >> Share

  93. HENSLEY SG, Hu MI, Bassett RL, Ying AK, et al
    Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-term Outcomes in 144 Patients Over Six Decades.
    J Clin Endocrinol Metab. 2024 Mar 4:dgae133. doi: 10.1210.
    >> Share

    February 2024
  94. JAGANNATH S, Mayilvaganan S
    Letter to the Editor from Jagannath and Mayilvaganan: "Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma".
    J Clin Endocrinol Metab. 2024 Feb 29:dgae117. doi: 10.1210.
    >> Share

  95. SARKAR R, Bolel P, Kapoor A, Eliseeva E, et al
    An Orally Efficacious Thyrotropin Receptor Ligand Inhibits Growth and Metastatic Activity of Thyroid Cancers.
    J Clin Endocrinol Metab. 2024 Feb 29:dgae114. doi: 10.1210.
    >> Share

  96. SCHOLFIELD DW, Lopez J, Eagan A, Antal Z, et al
    Response to Letter to the Editor from Jagannath and Mayilvaganan: "Is Multifocality a Predictor of Poor Outcome in Childhood and Adolescent Papillary Thyroid Carcinoma?".
    J Clin Endocrinol Metab. 2024 Feb 28:dgae118. doi: 10.1210.
    >> Share

  97. AHMADI S, Kotwal A, Bikas A, Xiang P, et al
    Outcomes of cytologically indeterminate thyroid nodules managed with Genomic Sequencing Classifier.
    J Clin Endocrinol Metab. 2024 Feb 28:dgae112. doi: 10.1210.
    >> Share

  98. VAN DER TUIN K, Ruano D, Knijnenburg J, van der Luijt RB, et al
    Clinically-relevant Germline Variants in Children with Non-Medullary Thyroid Cancer.
    J Clin Endocrinol Metab. 2024 Feb 28:dgae107. doi: 10.1210.
    >> Share

  99. MAINO F, Botte M, Dalmiglio C, Valerio L, et al
    Prognostic Factors Improving ATA Risk System and Dynamic Risk Stratification in Low- and Intermediate-Risk DTC Patients.
    J Clin Endocrinol Metab. 2024;109:722-729.
    >> Share

  100. STEGENGA MT, van Velsen EFS, Oudijk L, Verburg FA, et al
    Clinical and Histopathological Risk Factors for Radioactive Iodine Refractory Follicular and Oncocytic Thyroid Carcinoma.
    J Clin Endocrinol Metab. 2024 Feb 13:dgae084. doi: 10.1210.
    >> Share

  101. ALTSHULER B, Bikas A, Pappa T, Marqusee E, et al
    Non-Operative, Active Surveillance of Larger Malignant and Suspicious Thyroid Nodules.
    J Clin Endocrinol Metab. 2024 Feb 13:dgae082. doi: 10.1210.
    >> Share

    January 2024
  102. CONDELLO V, Poma AM, Macerola E, Vignali P, et al
    Prevalence, Molecular Landscape and Clinical Impact of DICER1 and DGCR8 Mutated Follicular-Patterned Thyroid Nodules.
    J Clin Endocrinol Metab. 2024 Jan 22:dgae034. doi: 10.1210.
    >> Share

  103. BHARADWAJ MS, Ballal S, Bal C
    Optimal Cumulative I-131 Activity in Metastatic Differentiated Thyroid Cancer: Balancing Efficacy and Adverse Events.
    J Clin Endocrinol Metab. 2024 Jan 12:dgae024. doi: 10.1210.
    >> Share

  104. BUCZYNSKA A, Kosciuszko M, Sidorkiewicz I, Wiatr AA, et al
    Enhancing Angioinvasion Assessment in Papillary Thyroid Cancer via a Biomarker Panel Involving TAC, 8-OHdG and Sortilin.
    J Clin Endocrinol Metab. 2024 Jan 5:dgae007. doi: 10.1210.
    >> Share

    December 2023
  105. KIM BH, Ryu SR, Lee JW, Song CM, et al
    Longitudinal changes in quality of life before and after thyroidectomy in patients with differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2023 Dec 23:dgad748. doi: 10.1210.
    >> Share

  106. PAPARODIS R, Livadas S, Karvounis E, Bantouna D, et al
    Elevated Preoperative TPO Ab Titers Decrease Risk for DTC in a Linear Fashion: A Retrospective Analysis of 1635 Cases.
    J Clin Endocrinol Metab. 2023;109:e347-e355.
    >> Share

  107. GOLDNER W
    The Role of Age in the Risk Assessment of Differentiated Thyroid Cancers.
    J Clin Endocrinol Metab. 2023 Dec 20:dgad743. doi: 10.1210.
    >> Share

  108. LIN S, Wang Z, Xing M
    Association between a History of Breast Cancer and Decreased Thyroid Cancer-specific Mortality.
    J Clin Endocrinol Metab. 2023 Dec 8:dgad722. doi: 10.1210.
    >> Share

  109. MU Z, Zhang X, Sun D, Sun Y, et al
    Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer.
    J Clin Endocrinol Metab. 2023 Dec 7:dgad697. doi: 10.1210.
    >> Share

  110. LEUNG AM, Brent GA
    Pregnancy - Does Promotion of Growth Extend to Thyroid Cancer?
    J Clin Endocrinol Metab. 2023 Dec 2:dgad707. doi: 10.1210.
    >> Share

  111. WANG Y, Zou B, Zhang Y, Zhang J, et al
    Comprehensive long-read sequencing analysis discloses the transcriptome features of Papillary Thyroid Microcarcinoma.
    J Clin Endocrinol Metab. 2023 Dec 1:dgad695. doi: 10.1210.
    >> Share

    November 2023
  112. YAMAZAKI H, Sugino K, Katoh R, Matsuzu K, et al
    Role of the degree of vascular invasion in predicting prognosis of follicular thyroid carcinoma.
    J Clin Endocrinol Metab. 2023 Nov 25:dgad689. doi: 10.1210.
    >> Share

  113. TORA R, Welch J, Sun J, Agarwal SK, et al
    Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome.
    J Clin Endocrinol Metab. 2023;108:3165-3177.
    >> Share

  114. LIU Q, Mao L, Zhang Z, Li G, et al
    Diagnostic Efficacy of FNA-Tg in DTC Cervical LN Metastasis and its Impact Factors: A Large Retrospective Study.
    J Clin Endocrinol Metab. 2023;108:3311-3319.
    >> Share

  115. FALCHETTI A
    New Perspective on the Genetic Dissection Underlying the Development of Parathyroid Cancer.
    J Clin Endocrinol Metab. 2023;108:e1751-e1752.
    >> Share

  116. LI P, Liu Y, Wei T, Wang X, et al
    Effect and interactions of BRAF on lymph node metastasis in papillary thyroid carcinoma with Hashimoto's thyroiditis.
    J Clin Endocrinol Metab. 2023 Nov 15:dgad667. doi: 10.1210.
    >> Share

    October 2023
  117. KWON H, Han KD, Moon SJ, Park SE, et al
    Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea.
    J Clin Endocrinol Metab. 2023 Oct 31:dgad575. doi: 10.1210.
    >> Share

  118. DAI P, Zhao W, Zheng X, Luo H, et al
    Effect of radioactive iodine therapy on cancer-specific survival of papillary thyroid cancer tall cell variant.
    J Clin Endocrinol Metab. 2023 Oct 7:dgad580. doi: 10.1210.
    >> Share


  119. Correction to "The Outcomes of First Reoperation for Locoregionally Recurrent/Persistent Papillary Thyroid Carcinoma in Patients Who Initially Underwent Total Thyroidectomy and Remnant Ablation".
    J Clin Endocrinol Metab. 2023 Oct 3:dgad573. doi: 10.1210.
    >> Share

    September 2023
  120. PALYGA I, Rumian M, Kosel A, Albrzykowski M, et al
    The frequency of differentiated thyroid cancer recurrence in 2302 patients with excellent response to primary therapy.
    J Clin Endocrinol Metab. 2023 Sep 28:dgad571. doi: 10.1210.
    >> Share

  121. XIAO WC, Li X, Shan R, Mei F, et al
    Pregnancy and progression of differentiated thyroid cancer: A propensity score-matched retrospective cohort study.
    J Clin Endocrinol Metab. 2023 Sep 20:dgad557. doi: 10.1210.
    >> Share

  122. POZDEYEV N, Dighe M, Barrio M, Raeburn C, et al
    Thyroid cancer polygenic risk score improves classification of thyroid nodules as benign or malignant.
    J Clin Endocrinol Metab. 2023 Sep 8:dgad530. doi: 10.1210.
    >> Share

  123. ILGAN S, Aydogan BI, Emer O, Anil C, et al
    Sonographic features of atypical and initially missed parathyroid adenomas: Lessons learned from a single center cohort.
    J Clin Endocrinol Metab. 2023 Sep 5:dgad527. doi: 10.1210.
    >> Share

    August 2023
  124. GILLIS A, Chen H, Wang TS, Dream S, et al
    Racial and Ethnic Disparities in the Diagnosis and Treatment of Thyroid Disease: a Mini- Review.
    J Clin Endocrinol Metab. 2023 Aug 30:dgad519. doi: 10.1210.
    >> Share

  125. HA EJ, Lee JH, Lee DH, Moon J, et al
    Artificial Intelligence Model Assisting Thyroid Nodule Diagnosis and Management: A Multicenter Diagnostic Study.
    J Clin Endocrinol Metab. 2023 Aug 25:dgad503. doi: 10.1210.
    >> Share

  126. JU G, Sun Y, Wang H, Zhang X, et al
    Fusion oncogenes in patients with locally advanced or distant metastatic differentiated thyroid cancer.
    J Clin Endocrinol Metab. 2023 Aug 25:dgad500. doi: 10.1210.
    >> Share

  127. LI H, Han R, Meng L, Sun Y, et al
    Nodal Metastases Associated with Fusion Oncogenes Are Age Dependent in Young Adult Patients with Thyroid Cancer.
    J Clin Endocrinol Metab. 2023 Aug 3:dgad458. doi: 10.1210.
    >> Share

    July 2023
  128. MERCADO M
    The Role of Androgen Receptors in Thyroid Cancer Biology: Beyond Sexual Dimorphism.
    J Clin Endocrinol Metab. 2023 Jul 15:dgad424. doi: 10.1210.
    >> Share

  129. NOEL JE, Sinclair CF
    Radiofrequency Ablation for Benign Thyroid Nodules.
    J Clin Endocrinol Metab. 2023 Jul 4:dgad357. doi: 10.1210.
    >> Share

    June 2023
  130. YAN L, Zhen Y, Li Y, Li X, et al
    Five-year Outcome Between Radiofrequency Ablation vs. Surgery for Unilateral Multifocal Papillary Thyroid Microcarcinoma.
    J Clin Endocrinol Metab. 2023 Jun 15:dgad360. doi: 10.1210.
    >> Share

  131. YEH MW
    The molecular landscape of thyroid nodules: Diagnostic and prognostic revelations from a large multicenter cohort.
    J Clin Endocrinol Metab. 2023 Jun 15:dgad362. doi: 10.1210.
    >> Share

  132. SATAPATHY S, Majeed AK, Ballal S, Bal C, et al
    Differentiated thyroid cancers in young adults versus children: Clinical characteristics and ten-year follow-up outcomes.
    J Clin Endocrinol Metab. 2023 Jun 7:dgad343. doi: 10.1210.
    >> Share

  133. ZHOU Y, Wang Y, Zhang Z, Yin X, et al
    Male sex is not a risk factor for prognosis in postoperative thyroid cancer patients: a propensity score matching study.
    J Clin Endocrinol Metab. 2023 Jun 2:dgad314. doi: 10.1210.
    >> Share

  134. BOJARSKY M, Baran JA, Halada S, Isaza A, et al
    Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated with Radioactive Iodine Therapy.
    J Clin Endocrinol Metab. 2023 Jun 2:dgad322. doi: 10.1210.
    >> Share

    May 2023
  135. LIN Y, Wu ZR, Shi YP, Ding M, et al
    Radiofrequency Ablation of Unifocal Papillary Thyroid Microcarcinoma With BRAF V600E Mutation.
    J Clin Endocrinol Metab. 2023 May 23:dgad269. doi: 10.1210.
    >> Share

  136. CHOU CK, Chi SY, Hung YY, Yang YC, et al
    Clinical impact of androgen receptor-suppressing miR-146b expression in papillary thyroid cancer aggressiveness.
    J Clin Endocrinol Metab. 2023 May 23:dgad279. doi: 10.1210.
    >> Share

  137. ALZAHRANI AS
    Clinical use of molecular data in thyroid nodules and cancer.
    J Clin Endocrinol Metab. 2023 May 18:dgad282. doi: 10.1210.
    >> Share

  138. SUN Y, Sun Q, Tian J, He X, et al
    Impact of waiting time for radioactive iodine therapy on outcome in N1 stage papillary thyroid cancer.
    J Clin Endocrinol Metab. 2023 May 11:dgad264. doi: 10.1210.
    >> Share

    April 2023
  139. ULLMANN TM, Sosa JA
    Delay in Surgery for Papillary Thyroid Cancer: A Proxy for Lower-Quality Care?
    J Clin Endocrinol Metab. 2023 Apr 21:dgad232. doi: 10.1210.
    >> Share

  140. CHIOSEA S, Hodak SP, Yip L, Abraham D, et al
    Molecular Profiling of 50,734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
    J Clin Endocrinol Metab. 2023 Apr 18:dgad220. doi: 10.1210.
    >> Share

    March 2023
  141. ALZAHRANI AS
    The risk of expanding risk stratification in thyroid cancer.
    J Clin Endocrinol Metab. 2023 Mar 29:dgad182. doi: 10.1210.
    >> Share

  142. CHAVES N, Broekhuis JM, Fligor SC, Collins RA, et al
    Delay in Surgery and Papillary Thyroid Cancer Survival in the United States: a SEER-Medicare Analysis.
    J Clin Endocrinol Metab. 2023 Mar 29:dgad163. doi: 10.1210.
    >> Share

  143. VAN VELSEN EFS, Verburg FA
    Adjuvant Radioiodine for Intermediate-Risk Papillary Thyroid Cancer - To Treat or Not To Treat.
    J Clin Endocrinol Metab. 2023 Mar 25:dgad171. doi: 10.1210.
    >> Share

  144. KESBY N, Mechera R, Fuchs T, Papachristos A, et al
    Natural History and Predictive Factors of Outcome in Medullary Thyroid Microcarcinoma.
    J Clin Endocrinol Metab. 2023 Mar 25:dgad173. doi: 10.1210.
    >> Share

  145. NASR CE
    Can one predict long-term growth of cytologically-benign thyroid nodules?
    J Clin Endocrinol Metab. 2023 Mar 22:dgad160. doi: 10.1210.
    >> Share

  146. JHA S, Welch J, Tora R, Lack J, et al
    Germline and somatic inactivating FLCN variants in parathyroid cancer and atypical parathyroid tumors.
    J Clin Endocrinol Metab. 2023 Mar 20:dgad136. doi: 10.1210.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016